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The field of pharmaceutical cocrystals has reached a tipping point, particularly because cocrystals can
improve the physicochemical properties of drugs without compromising their therapeutic benefit.
Accounts of cocrystal investigations in the literature started in earnest in 2003 and patent applications
soon followed. The frequency of both has steadily accelerated, demonstrating an enhanced
understanding of the design, characterisation, and manufacture of cocrystals and heightened interest
from industry. Indeed, there were four new product approvals from 2014 to 2017 and more are in the
pipeline. Here, we review all marketed drug products that are based upon pharmaceutical cocrystal drug
substances, starting with the first recorded example, Beta-Chlor1 in 1963, with a particular emphasis on
their discovery, rationale for use, and market impact.Introduction
Solid form optimisation: serendipity or design?
In 2013, Merck and Pfizer announced a joint collaborative effort to
bring a promising new antidiabetic, Steglatro1, to market [1]. They
closed out 2017 by obtaining US Food and Drug Administration
(FDA) approval with analysts predicting blockbuster status for
their compound [2,3]. Steglatro1, a molecular cocrystal of ertugli-
flozin and L-pyroglutamic acid, is the latest in a recent flurry of
drug approvals made possible by crystal engineering principles
developed during the early 2000s which include: Odomzo1
(cocrystal of sonidegib and phosphoric acid), Suglat1 (cocrystal
of ipragliflozin and L-proline), and Entresto1 (cocrystal of valsar-
tan and sacubitril). The story of how academic curiosity and
advances in X-ray diffraction enabled the field of crystal engineer-
ing to grow rapidly has been covered in detail in the literature
[4,5]. Academic and industry researchers were quick to uncover the
potential of the cocrystal approach to manipulate the physical
properties of the solid state, particularly in an application area
where the solid state is so valuable: pharmaceuticals [6,7]. This isPlease cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
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https://doi.org/10.1016/j.drudis.2018.11.023 part of an aspect of preclinical research that has been termed
‘Molecules, Materials and Medicines’, or M3 [8].
It is no secret that many new chemical entities suffer from low
solubility and/or poor permeability; up to 90% of new drugs
receive BCS II classification [9]. This presents a major challenge
for pharmaceutical science. If a drug cannot dissolve in the gas-
trointestinal tract (GIT) or penetrate tissues, then it will have
difficulty finding therapeutic use. For decades, formulation scien-
tists have been using solid form optimisation strategies, such as
those summarised in Fig. 1 [10]. Each strategy brings its own
advantages and disadvantages, each to be weighed against
manufacturing challenges, regulatory risks, and the desired mode
of action of the drug substance in question.
Cocrystals are ‘ . . . solids that are crystalline single-phase mate-
rials composed of two or more different molecular and/or ionic
compounds generally in a stoichiometric ratio which are neither
solvates nor simple salts.’ [11]. Cocrystallisation in relation to phar-
maceutical science is an area that has grown rapidly since several key
publications in 2003–2004 demonstrated how crystal engineering
can be applied to drug substances such as aspirin [7], ibuprofen [7],
fluoxetine [12], carbamazepine [13], and itraconazole [14]. These
landmark papers came about at least in part because the field ofrendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 1
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FIGURE 1
Summary of approaches to solid form optimisation.
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ty, exemplified by the discovery of the first cocrystal (urea and NaCl)
in 1783 [15], had been replaced by crystal design principles. Figure 2
reveals the impact of these papers on the academic community,
namely an almost exponential rise in publications on the topic of
cocrystals after 2004, which has been mirrored by a similar trend in
the frequency of patent applications relating to cocrystals. Although
the term ‘cocrystal’ is also used in structural biology, search terms
were used to minimise hits for these publications while minimising
the omission of pharmaceutical cocrystals.
In this review, we explore how pharmaceutical cocrystals have
emerged and present an overview of existing examples of inten-
tional and nonintentional FDA-approved pharmaceutical cocrys-
tal drug products. We also discuss how regulatory ambiguity
initially made it difficult to advance the field, particularly in a
risk-adverse industry, such as pharmaceuticals. Finally, we look
ahead to the future of pharmaceutical drug products by examining
pharmaceutical cocrystal products in the clinical pipeline and
assessing the potential impact of cocrystals on current commonly
prescribed drugs.
The cocrystal advantage
Regulatory green light
The pace and complexity of scientific innovation can make it diffi-
cult for public bodies to construct an appropriate regulatory frame-Please cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023
2 www.drugdiscoverytoday.comwork to maintain the fine balance between safety and allowing new
technologies to thrive. Statutory instruments do not always get it
right and, invariably, this maintains the status quo. Fenwick et al.
provide an excellent analysis of this problem and highlight ways in
which regulators can promote innovation (such as those used in the
financial industry) so that ultimately the customer or patient can
benefit from the latest innovative technology [16].
Unfortunately for the field of cocrystals, the status quo was
maintained in February 2011, when the FDA published their draft
guidance on the subject of cocrystals, defining them as ‘solids that
are crystalline materials composed of two or more molecules in the
same crystal lattice’. Here, they also considered cocrystals to be
drug product intermediates (or in process materials) that are
subject to additional manufacturing regulations under current
good manufacturing practice requirements [17]. This made the
risk-adverse pharmaceutical industry hesitant to spend research
and development resources developing a troublesome solid form.
A seminal review paper that evolved from an Indo–US Bilateral
Meeting explored the scientific debate regarding nomenclature of
cocrystals and suggested that cocrystals should be classified with
salts and how the FDA might approach reclassification of phar-
maceutical solids [11]. Since then, further classification has been
proposed [18]. Despite this paper and others like it (e.g., [19]), the
FDA remained firm, releasing their full guidance document in
2013, which reinforced their previous perspective.rendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
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FIGURE 2
Cocrystal publications from 2001 to 2018 generated from a search of the Web of Science1 database for terms ‘cocrystal’ OR ‘co-crystal’ NOT ‘structural biology’
NOT ‘structural basis’ (13 August 2018) (black bars) versus number of cocrystal patents from 2001 to 2018 generated from a search of the US Patent and
Trademark Office Database for terms ‘cocrystal’ OR ‘co-crystal’ (10 August 2018) (white bars).
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recently returned since the FDA modified their guidance in Febru-
ary 2016. This draft guidance classified cocrystals as active phar-
maceutical ingredients (APIs), not drug product intermediates,
and endorsed cocrystals as equivalent to polymorphs or salts of
the API. This is potentially a significant development because it
could enable both proprietary and generic companies to access the
505(b)(2) pathway for drug approval in the USA. The FDA released
the final version of the Guidance in February 2018 [20].
FDA 505(b)(2) regulatory pathway
A key concept in the utilisation of cocrystals is that there is no
change in the molecular structure of the medicine. This was
recognised by the FDA in their recent guidance document in
which they specifically state that ‘cocrystals are considered the
same as polymorphs or salts of the API from a regulatory
perspective’ [20], a welcome change from years previous. This
could enable drug companies to seek FDA approval for their
medicines using data from previous safety and efficacy investiga-
tions to bring a new product to market. Through 505(b)(2), com-
panies can submit applications for medicines with new
indications, substitutions of active ingredients, or (in the case of
cocrystal applications) changes to the solid form [21]. In this way,
the FDA has reduced the regulatory and financial burden to
encourage innovation so that patients ultimately reap the benefits
of the latest medicinal advances as soon as possible.
In Europe, the European Medicines Agency (EMA) released a
reflective document in 2015 that classified cocrystals in a similar
way to salts of the API [22]. Under their regulations, it means that
the cocrystal is considered to be the same as the API unless it
demonstrates different pharmacokinetic properties, an approach
that industry considered more palatable. Today, a regulatory
approval route similar to the 505(b)(2) is based on Article 10 of
Directive 2001/83/EC where ‘ . . . different salts, esters, ethers,
isomers, mixture of isomers, complexes or derivatives of an active
substance shall be considered to be the same active substancePlease cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023unless they differ significantly in properties with regard to safety
and/or efficacy.’ [22]
Intellectual property opportunities
Recent estimates put the cost of developing a new drug at US$2.8
billion [23]. Furthermore, the number of approved drugs per
billion of spending has halved each year since the 1950s. This
ultimately drives up costs and puts further strain on global health-
care resources. Here, crystal engineering can offer a solution
because new intellectual property (IP) opportunities exist for
innovators who develop cocrystals of new and existing medicines,
particularly if it results in improvement of pharmacokinetic char-
acteristics of the API. This in turn may allow the drug to be used
against different indications, enable manufacture, or improve
purity of the final drug product [24]. Companies have begun to
recognise the utility of cocrystals and this is evident by the addi-
tion of the phrase, ‘the drug and any pharmaceutically acceptable
cocrystals’ to patents of new drug molecules [25]. There is also an
opportunity for generic manufacturers to develop novel solid
forms to overcome patent protection on existing marketed com-
pounds.
Improved physiochemical properties
Although the diversity of possible crystal packing arrangements
makes it difficult to predict the properties of a selected API and
coformer upon crystallisation [26], Aakero¨y et al. reported that
coformers can be selected to systematically change the properties
of solid forms. They demonstrated that increasing the carbon
chain length of coformers leads to predictable decreases in solu-
bility [27]. This concept could be applied to alter the pharmacoki-
netics of an API, which can result in drugs previously shelved
finding their way into the clinic. Furthermore, because the cocrys-
tal form may enable greater solubility and subsequent absorption
of the API, one might find that less API is required in the dosage
form, as is the case with Entresto1 [28].
When a kinetically stable solid form is conferred by cocrystalli-
sation, pharmacokinetics can exhibit what is known as the ‘springrendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 3
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Guzma´n et al. and reflects the situation whereby a higher energy
form ‘springs’ drug solubility past its solubility limit and agents,
such as surfactants, can be used to maintain this state (the para-
chute) [29]. The use of higher energy forms [30] and the impor-
tance of the supersaturation state [31] are not new concepts in
pharmaceutical science, indeed, they were first documented by the
Higuchi brothers during the 1960s [30,31] and are now applied in
the field of cocrystals. Work is ongoing in this area to understand
the mechanism of cocrystal solubility [32–34] and study the effects
of endogenous conditions on this mechanism [35]. Other proper-
ties conferred by cocrystals include improved tabletability [36],
reduced hygroscopicity [37] increased permeability [38], and con-
trolling drug release rates [39], among others explored in several
reviews [6,40,41].
Crystal engineering in pharmaceuticals
Crystal engineering is a term first coined by Pepinsky in 1955 [42]
and implemented by Schmidt in 1971 [43]. Desiraju [5] and Etter
[44] later identified, characterised, and utilised the supramolecular
interactions to generate new solid forms [45]. Today, crystal
engineering is a diverse field, as detailed in recent reviews [4,5].
In pharmaceutical science, the ability to rationally select cofor-
mers for a desired API is a cornerstone of the field [6]. This design
approach is enabled by the discovery of pharmaceutically relevant
supramolecular synthons, which are subsequently ranked by the
propensity of formation to generate a synthon hierarchy [13,46–
50]. Although not predictable 100% of the time, such understand-
ing provides a reasonable expectation that crystal engineers can
take any API and develop a cocrystallisation strategy.
There are two main classifications of cocrystals, ionic cocrystals
(or charge assisted) and molecular cocrystals. There are important
differences. First, molecular cocrystals generally comprise two
components, a biologically active molecular compound and a
pharmaceutical acceptable molecular coformer. Ionic cocrystals
must have an additional variable because they comprise at least
three moieties: an anion, a cation, and a neutral component, one
of which is biologically active. This additional variable creates an
exponentially larger array of possible compositions and increased
likelihood of uncovering a solid form with desirable characteris-
tics. Second, ionic cocrystals are sustained by charge-assisted
supramolecular synthons, which are less likely to be impacted
by solvent and more likely to afford large property variations [51].
Overcoming cocrystal disadvantages
Based upon the above, it can be asserted that cocrystals offer a low-
risk, low-cost, but high reward route to new and better medicines.
In essence, cocrystals offer a means to control the physiochemical
properties of a medicine by addition of a suitable coformer.
Coformers should be cheap, pharmaceutically acceptable, of low
molecular weight, and have multiple API-binding sites with the
ability to form strong intermolecular interactions. These are not
necessarily big hurdles to overcome, but they cannot be ignored.
Furthermore, although cocrystals are no longer different to a salt
from a regulatory perspective, there is nervousness about large-
scale cocrystal manufacture. There are also concerns that addition
of a coformer will contribute to a higher mass of dosage form. This
could become unmanageable for drugs such as paracetamol, met-
formin, or valproic acid, where the dose of the drug product is on
the gram scale. However, this apparent disadvantage can be mini-Please cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023
4 www.drugdiscoverytoday.commised by use of coformers with multiple binding sites to create a
solid form with a 3:1 or 2:1 stoichiometric drug:coformer ratio.
Additionally, a strategy whereby the salt of the drug can be crystal-
lised with the parent acid or base can also be used, as was the case
with Epilim1, which exists as a 3:1 cocrystal of sodium valproate
and valproic acid [52].
Commercially available cocrystals
Serendipity has a role in almost all great scientific discoveries, from
microwaves to superglue to penicillin to Teflon. Naturally, scien-
tists are reluctant to announce that luck was involved in their
latest discovery, but novelty can only be uncovered and exploited
when supported by scientific understanding. The ability of scien-
tists to apply the scientific method to a surprising result is what can
make unexpected discoveries all the more remarkable. The phar-
maceutical industry is no stranger to this concept, because it
regularly uses a screening strategy designed to induce the propen-
sity of serendipity [53]. Indeed, as we discuss herein, many of the
compounds highlighted earlier owe much to serendipity from
their discovery, clinical application, and subsequent solid form
optimisation. Herein, we address examples of both serendipity and
rational design.
Serendipitous discoveries
Chloral betaine, Beta-Chlor1
Some years have passed since chloral betaine was referred to as the
‘modern morphine’ in Stoker’s Dracula’ [54], but its presence in the
clinic today (although limited) is a testament to its success. Al-
though the US patent described its preparation in 1962 as being
designed to primarily mask the unpleasant taste of chloral [55],
that it is indeed a cocrystal was only revealed in 2016 [56]. This
investigation by the Zaworotko group revealed that chloral betaine
exists as a charge-assisted diol-carboxylate heterodimer, with fur-
ther Cl  O interactions forming a tetramer. The cocrystal confers
increased thermal stability over the pure drug substance, an ad-
vantage that was clearly unanticipated by the original patent
inventors [56].
Chloral has a long history; it was the first synthetic sedative,
having been synthesised in 1832. It took the curiosity of the
German pharmacologist Liebreich to uncover its sedating proper-
ties and facilitate its widespread use (and abuse) thereafter [57].
Indeed, toxicological analysis revealed that it was part of the
cocktail that resulted in the death of Marilyn Monroe [58]. Erro-
neously, it was thought to liberate chloroform in vivo, thereby
explaining its sedative effects. Chloral is now known to be a
prodrug of trichloroethanol, which exhibits its effects via action
on GABAA receptors [59]. Chloral gained notoriety as a key item in
the toolkit of Mickey Finn, a bartender from Chicago who used its
potent properties to sedate and rob his customers.
Valproate semisodium, Depakene1
The use of valproic acid as a carrier for organic compounds is well
documented and it stocked the shelves of laboratories globally
during the early 20th century [60]. Scientists of that time knew
little of the power of this humble agent, and its subsequent impact
on the treatment and prevention of seizures for millions of
patients. It was discovered and subsequently approved for epilepsy
in France in 1967. Although it was originally thought to be
moderately useful, its full potential was realised in Germany,rendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
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Today, it is sold in various forms under Depakene1, Depakote1, or
Epilim1, and the clinical literature makes a distinction between
three forms of valproate: valproic acid (free acid), sodium valpro-
ate (salt), and semisodium valproate (cocrystal) [52]. There is no
evidence to suggest that administration of any particular form
effects clinical outcomes; thus, they are considered bioequivalent.
The British National Formulary notes, ‘Semisodium valproate com-
promises equimolar amounts of sodium valproate and valproic
acid’ and ‘Convulex1 has a 1:1 dose relationship with products
containing sodium valproate . . . care is needed if switching or
making changes’.
The cocrystal structure contains a 3:1 ratio of sodium valproate
and valproic acid, which has a sodium oxygen cluster surrounded
by the lipophilic tail of valproate [52]. Despite the existence of
several forms of valproate, the cocrystal formulation demonstrates
superior solid form properties, particularly by reducing the hygro-
scopicity found with sodium valproate and valproic acid [61,62].
Clinically, the cocrystal is the dominant solid form for tablet
formulations [63].
Caffeine citrate, Cafcit1
Citrated caffeine, or caffeine citrate, is another cocrystal that has
stood the test of time. The British Pharmaceutical Codex 1907
suggested that caffeine citrate has higher stability than the pure
alkaloid in concentrated solution [64], and it was known previ-
ously as a complex of caffeine and citric acid until its structural
characterisation in 2007 [65]. X-ray diffraction analysis revealed
that the cocrystal is sustained by O–H  N hydrogen bonds be-
tween carboxylic acid groups of citric acid and imidazole moieties
of caffeine. Additional O–H  O hydrogen bonds create a ring-like
motif with alternating molecules of caffeine and citric acid [65].
Caffeine exhibits its effect as an adenosine antagonist and this
results in stimulation of the respiratory centre, leading to in-
creased sensitivity to carbon dioxide, which in turn increases
respiratory rate and oxygen consumption [66]. Although a certain
fraction is converted to theophylline in vivo (a commonly pre-
scribed bronchodilator), it is the preferred agent to treat infantile
apnoea because of its minimal adverse-effect profile. Cafcit1 is a
favourite case study to highlight how overdoses can occur, partic-
ularly because the dose of caffeine is half that of caffeine citrate.
The danger is compounded because of changes in neonatal phar-
macokinetics that influence the half-life of caffeine from 3–4 days
in newborn infants to 5 h after 9 months. This case highlights the
need for crystallographers to engage with clinicians to ensure that
understanding of cocrystal drug forms is appropriately incorpo-
rated into clinical curricula.
Escitalopram oxalate, Lexapro1
Escitalopram is the left-handed configuration of the popular anti-
depressant citalopram, a racemic mixture of the two stereoisomers.
Escitalopram is marketed as a cocrystal containing the escitalo-
pram oxalate salt and oxalic acid, whereas citalopram is approved
as the hydrobromide salt. Lexapro1 gained a lot of press because of
controversies regarding the ‘obviousness’ of this new structural
enantiomer [67]. Although the developers ultimately succeeded in
demonstrating the novelty of their enantiomer, the discovery of a
new, patentable cocrystal form of this drug [68] was likely a heart
sink moment for executives at Forest and Ludbeck laboratories.
This synthon contains the escitalopram cation forming a salt byPlease cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023way of two hydrogen bonds to the same oxalate dianion [N+–H  
(O,O)]; this unit is linked into chains by a neutral oxalic acid
molecule [68].
Recently, a ground-breaking network meta-analysis published
in The Lancet concluded that escitalopram, agomelatine, and
vortioxetine are the most effective and tolerable antidepressants
available [69]. These results could influence current clinical prac-
tice, but some remain sceptical [70].
Sonidegib diphosphate, Odomzo1
Novartis discovered sonidegib, the second FDA-approved inhibitor
of smoothened, a transmembrane protein involved in the Hedge-
hog pathway that is responsible for the transcription of several
glioma-associated oncogenes [71]. Using rational drug design and
computational analysis to screen over 10 000 compounds, the
company subsequently refined its selection using structure–activi-
ty relationships to generate the lead compound [72].
Although monophosphate cocrystals with phosphoric acid
have been designed previously [73], there is no published evidence
that Odomzo1 is a cocrystal by design. However, there is evidence
to the contrary; the FDA chemistry review contains a reviewer
comment that notes, with brevity, ‘API is not a salt’ [74]. In
addition, the original patent application refers to mono- and
diphosphate salts of the API [75]. Furthermore, an EMA assessment
states that, although prepared as a cocrystal, it can breakdown on
contact with water and they noted that this does not change
absorption [76]. From this, one can conclude that it is unlikely
that the sonidegib diphosphate cocrystal was created by design,
notwithstanding the manufacturing problems it produced [76].
The EMA document states that this structure is known and that
it contains the salt of sonidegib with phosphate, with another
phosphate free acid to make a diphosphate cocrystal [76]. Al-
though patent literature does not reveal the precise crystal struc-
ture, it does refer to several other cocrystals [77].
Crystal engineering of pharmaceutical cocrystals
Ipragliflozin L-proline, Suglat1
Suglat1 represents a purposeful step of ‘Big Pharma’ into the
cocrystal field; coincidently, it is also the first approved sodium
glucose co-transporter 2 (SGLT2) inhibitor in Japan. It was devel-
oped by Astellas and Kotobuki pharmaceuticals and was approved
for use in Japan in 2014. Since its release, Astellas has recorded a
year-on-year increase in sales, currently standing at ¥9.5 billion for
the 2016 financial year [78]. Even in the face of fierce competition
from dapagliflozin, canagliflozin, empagliflozin, among others,
this product remains dominant, with 30% share of the Japanese
market [78].
The team at Astellas and Kotobuki have described their steps
towards discovery of the active moiety [79]. They opted for a
crystal engineering approach because the parent compound form
can switch reversibly from an anhydrous form to a nonstoichio-
metric hydrate depending on the storage conditions. The cocrystal
form (ipragliflozin  L-proline) has consistent quality, does not
absorb moisture, and was suitable to be brought forward into the
drug product [80]. Suglat1 is one of several success stories involv-
ing SGLT2 inhibitors, the role of which in diabetes pharmacother-
apy is discussed in a pharmacological review by Gallo et al., who
noted that the results of ongoing long-term studies will determine
the future of this therapy [81].rendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 5
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The first multidrug cocrystal and the second case of cocrystal
innovation from Novartis, Entresto1 is a multidrug formulation
that combines the angiotensin receptor inhibitor valsartan with a
neprilysin inhibitor prodrug, sacubitril. Entresto1 is a classic
example of how cocrystals can influence pharmacokinetics. This
formulation improves the bioavailability of valsartan, with a lower
dose required to achieve the same therapeutic effect [28].
Although it contains valsartan, a drug approved by Novartis in
2002 [82], it is this addition of the first-in-class neprilysin inhibitor
that sets this drug apart. Clinicians might be hesitant to prescribe
Entresto1 after the National Institute of Health and Clinical
Excellence published an analysis of the much-publicised PARA-
DIGM-HF trial [83], coupled with the significant cost differential
between Entresto1 (s1807) and other treatment options, such as
valsartan (s109) or ramipril (s51) [28]. Despite this, Novartis
reported profits of US$507 m in 2017, and recent reports suggest
it could reach revenues of US$4–5 billion per year [84]. The
formation of the large complex structure illustrates how unpre-
dictable crystal structures can be, with the unit cell containing six
sacubitril and six valsartan anions, 18 penta- and hexa-coordinat-
ed sodium cations, along with 15 water molecules [85].
Ertugliflozin L-pyroglutamic acid, Steglatro1
The second SGLT2 inhibitor as a cocrystal form was approved in
2017, emerging from Pfizer and Merck’s collaborative efforts in
previous years [1]. Similar to Odomzo1, this compound was
generated by rational design using computational and high-
throughput screening [86] and was ultimately selected because
a suitable crystalline form of ertugliflozin itself was not found and
it was not ionisable at physiological pH. Therefore, the team at
Pfizer decided to pursue a cocrystallisation strategy [86]. Patent
literature reveals that they uncovered three cocrystal forms of
ertugliflozin: a 1:1 cocrystal with L-pyroglutamic acid (the mar-
keted form) and 1:1 and 1:2 cocrystals with L-proline [87]. This is
the second case for drugs within the SGLT2 class in which
cocrystallisation was exploited to create a solid form suitable
for manufacture and subsequent clinical application. Steglatro1
was approved alongside Steglujan1 [2], a fixed-dose combination
containing ertugliflozin and sitagliptin, which demonstrates the
robustness of the cocrystal form and the diversity of applications
it can take (Table 1).
Pharmaceutically approved complexes suspected to be
cocrystals
There are numerous examples within the scientific literature of
drugs identified as ‘complexes’, although their exact structuralPlease cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023
TABLE 1
Summary of commercially available pharmaceutical cocrystals
Drug Date of FDA approval Compon
Beta-Chlor1 1963 Chloral h
Depakote1 1983 Valproic 
Cafcit1 1999 Caffeine
Lexapro1 2002 [Escitalop
Suglat1 2014 Ipragliflo
Entresto1 2015 [Valsartan
Odomzo1 2015 [Sonideg
Steglatro1 2017 Ertugliflo
6 www.drugdiscoverytoday.comcharacteristics are yet to be determined. Indeed, it was only in 2016
that the crystallographic structure of chloral betaine was uncov-
ered after 100 years of clinical use [56]. This prompted a search of
the PubChem database using the terms ‘complex’ AND ‘molecular
complex’ and manual searches of the British Pharmaceutical Codex
1907 and British National Formulary 74. We thereby identified
several potential pharmaceutical cocrystals through this approach
(Table 2), but suspect there might be others.
Interestingly, King’s American Dispensatory 1898 described how
some of these complexes can be generated. For example, caffeine
citrate is prepared as follows, ‘dissolve the citric acid in the hot
distilled water, add the caffeine, and evaporate the resulting solu-
tion, on a water bath, to dryness, constantly stirring towards the
end of the operation’ [88]. Those in the field of cocrystallisation
will notice the similarities here to the slurrying approach that has
been used for cocrystal discovery and scale-up [89]. It appears that,
if one looks through old pharmacy texts, one might find robust
methodologies to create cocrystals of the above for further char-
acterisation. This list, and potential additions to it, provides scope
for crystallographers to investigate the nature of these complexes;
perhaps with a little luck there are interesting crystal engineering
insights yet to be uncovered.
The future of cocrystals
Recent developments suggest that the field of pharmaceutical
cocrystals has many fruits to bear, not least in finding new crystal
forms, and the potential IP that might accompany such discover-
ies. There is also a developing understanding of how cocrystals
behave in physiological environments and particularly how
cocrystallisation could be applied to alternative routes of delivery.
We also note that tentative steps have been taken by the pharma-
ceutical industry in the field of cocrystallisation, but there are still
outstanding challenges, particularly with regards to continuous
manufacturing. A recent review discusses how emerging process
analytical technologies and continuous processing techniques can
be applied to cocrystallisation [89].
Clinical trials
ClinicalTrialsRegister.eu and ClinicalTrials.gov were searched
using the terms, ‘Cocrystal’ OR ‘Co-crystal’ and the results were
compiled into Table 3.
Cocrystals of commonly prescribed drugs
The burst of literature activity since 2003 has resulted in an
eclectic mix of cocrystals using pharmaceutically relevant
compounds. A search of the Cambridge Structural Databaserendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
ents Indication
ydrate  betaine Sedation
acid  [valproate sodium] Epilepsy
  [citric acid] Infantile apnoea
ram oxalate]  Oxalic acid Depression
zin  L-proline Diabetes
 sodium]  [sacubitril sodium] Heart failure
ib monophosphate]  phosphoric acid Basal cell carcinoma
zin  L-pyroglutamic acid Diabetes
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TABLE 2
Summary of potential pharmaceutical cocrystalsa
Drug Components Indication Source
Dichloralphenazone Antipyrine, chloral hydrate (1:2) Migraine PubChem CID 10188
Iron sorbitex Iron, sorbitol, sodium citrate (1:1:1) Iron deficiency anaemia PubChem CID 20715017
Nicotinamide–ascorbic acid Nicotinamide, ascorbic acid (1:1) Vitamin complexes PubChem CID 54710212
Tetracycline phosphate Tetracycline, phosphoric acid (1:1) Broad-spectrum antibiotic PubChem CID 54713149
Caffeine–sodium benzoate Caffeine, sodium benzoate (1:1) Headache British Pharmaceutical Codex 1907
Caffeine–sodium salicylate Caffeine, sodium salicylate (1:1) Headache British Pharmaceutical Codex 1907
Acridine–sulfonamide Acridine, sulfonamide (1:1) Antiseptic PubChem CID 54710212
a Compounds were identified as pharmaceutically approved ‘complexes’ from manual searches of PubChem database using the terms ‘complex’ AND ‘molecular complex’ and of the
British Pharmaceutical Codex 1907 and British National Formulary 76.
TABLE 3
Summary of cocrystal products currently in clinical trialsa
Drug Phase Company Clinical trial identifier
TAK-020 (TAK-020–gentisic acid) Phase I Takeda Pharmaceuticals NCT02723201
E-58425 (tramadol hydrochloride–celecoxib) Phase III Esteve NCT03108482
CC-31244 (non-nucleoside polymerase inhibitor) Phase IIa Cocrystal Pharma NCT0276075
T121E01F/T121E02F (zoledronic acid cocrystal) ‘Phase III ready’ Thar Pharmaceuticals NCT01721993
a Compounds were identified from searches of ClinicalTrialsRegister.eu and ClinicalTrials.gov using the terms ‘Cocrystal’ OR ‘Co-crystal’.
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FIGURE 3
Selection of commonly prescribed drugs contained within the British National Formulary 76 and number of cocrystal forms found on the Cambridge Structural
Database (July 2018).
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Nwas conducted using ConQuest (v1.2.2, 2018) to determine the
number of cocrystal forms of drugs that are commonly pre-
scribed in the UK and Ireland. Figure 3 displays the results and,
evidently, some compounds generate greater interest than
others. Unsurprisingly, paracetamol, aspirin, and caffeine
are among those with the greatest research activity, perhaps
because of their ubiquity in academic labs as opposed to crystal
novelties. It is clear that there is much scope for cocrystal
research, and the benefits here are not just limited to trouble-Please cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023some compounds, because they can improve the utility of even
the most widely prescribed medicines.
A comprehensive review in 2009 [41], followed by others in 2013
[90] and 2016 [6], illustrated the diversity of solid form changes that
can occur upon cocrystallisation and reinforced how crystal engi-
neering principles can create more desirable solid forms for use in
pharmaceutical development. The numerous advantages brought
by cocrystallisation can be compounded by the inclusion of a second
API, as seen with Entresto1 [24]. Here, paracetamol–indomethacin,rendipity to design to application, Drug Discov Today (2018), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 7
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Review
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EENsildenafil–aspirin, or piracetam–lithium all show promise from a
chemical and clinical perspective [91].
Concluding remarks
The road is clear for cocrystals to become an integral, accepted,
and, possibly, preferred part of solid form screening for the mate-
rials side of drug development. Some early examples of commer-
cial cocrystals might have been serendipitous but advances in
crystal engineering have enabled their design by crystal engineer-
ing. Concurrent advances in technology have enabled rapid and
accurate structural characterisation of novel cocrystals. Regula-
tions, skills, and history are all in hand; now it is time to capitalise.
Market routes, including regulatory approval, have been recently
demonstrated for the aforementioned pharmaceutical cocrystals
and market performance is more than encouraging. Furthermore,Please cite this article in press as: Kavanagh, O.N. et al. Pharmaceutical cocrystals: from se
drudis.2018.11.023
8 www.drugdiscoverytoday.comthere is opportunity for the development of bioequivalent cocrys-
tals for use in generic products. Therefore, there is every reason to
expect an increase in the number of approved pharmaceutical
cocrystal drug products in the coming years. However, there
remain challenges regarding rational selection of coformer librar-
ies, optimised screening methods, scaled-up manufacturing
routes, and the impact of a cocrystal formulation on the dosage
mass. We could now be beginning to enter an era of pharmaceuti-
cal cocrystal dominance: watch this space!
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